Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
نویسندگان
چکیده
منابع مشابه
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Mutations in the BRAF oncogene occur in the majority of melanomas, leading to the activation of the mitogen-activated protein kinase pathway and the transcription of downstream effectors. As BRAF and its effectors could be good melanoma therapy targets, defining the repertoire of genes that are differentially regulated because of BRAF mutational activation is an important objective. Towards thi...
متن کاملAntitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells. Somatic mutations in BRAF and NRAS are frequently observed in melanoma. Recently, the BRAF inhibitors vemurafenib and dabrafenib have emerged as promising agents for the treatment of melanoma patients with BRAF-activating mutations. However, as BRAF inhibitors indu...
متن کاملMitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor
Vemurafenib/PLX4032, a selective inhibitor of mutant BRAFV600E, constitutes a paradigm shift in melanoma therapy. Unfortunately, acquired resistance, which unavoidably occurs, represents one major limitation to clinical responses. Recent studies have highlighted that vemurafenib activated oxidative metabolism in BRAFV600E melanomas expressing PGC1α. However, the oxidative state of melanoma resi...
متن کاملImmunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
Therapy options for patients with advanced stage melanoma have improved steadily over the past decade, with recent clinical successes noted for BRAF inhibitors (BRAFi). BRAFi such as dabrafenib are highly specific for BRAF mutant, BRAF, which is expressed in approximately 50% of melanomas. Although treatment with BRAFi is highly efficacious with substantial tumor regression and increased patien...
متن کاملDegradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi-resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that naïve melanoma cells undergo autophagy and re-express argininosuccinate synthetase 1 (ASS1) to ena...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pathology & Oncology Research
سال: 2020
ISSN: 1219-4956,1532-2807
DOI: 10.1007/s12253-020-00837-9